Histogen, Inc. (HSTO)
| Market Cap | 5.79M |
| Revenue (ttm) | 4.36M |
| Net Income (ttm) | -11.35M |
| Shares Out | 2.50M |
| EPS (ttm) | -5.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Jun 3, 2022 |
| Volume | 43,664 |
| Open | 2.38 |
| Previous Close | 2.34 |
| Day's Range | 2.28 - 2.52 |
| 52-Week Range | 2.06 - 22.80 |
| Beta | -0.17 |
| Analysts | Buy |
| Price Target | 45.90 (+1,878.4%) |
| Earnings Date | Aug 10, 2022 |
About HSTO
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, whi... [Read more...]
Financial Performance
In 2021, Histogen's revenue was $1.03 million, a decrease of -49.88% compared to the previous year's $2.06 million. Losses were -$14.95 million, -20.35% less than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for HSTO stock is "Buy." The 12-month stock price forecast is 45.9, which is an increase of 1,878.45% from the latest price.
News
Histogen Announces 1-for-20 Reverse Stock Split
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective...
Histogen to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective ...
Histogen Reports First Quarter 2022 Financial Results and Provides Business Update
Received $3.75 Million Payment from Allergan
CORRECTING and REPLACING Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D.
SAN DIEGO--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: PARACRINE ANNOUNCES APPOINTMENT OF BIOTECH VETERAN DAVID...
Paracrine Announces Appointment of Biotech Veteran David Crean, Ph.D. to the Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., a company developing its novel cell therapy platform in late-stage clinical trials in advanced wound care, announced today the appointment of David Crean, Ph...
Histogen to Report First Quarter 2022 Financial Results and Provide Business Update
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selectiv...
5 Top Biotech Penny Stocks Under $1 To Watch This Week
Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information...
Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today
Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information | Pe...
Histogen Announces Closing of $4.75 Million Private Placement
SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natura...
Histogen Announces $4.75 Million Private Placement
SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natura...
Histogen Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoing with Top-Line Data Anticipated in the First Half of 2023 Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoi...
Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business Update
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the ...
Histogen Announces Closing of $3.5 Million Private Placement
SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural...
Histogen Announces $3.5 Million Private Placement
SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural...
Histogen Reports Third Quarter 2021 Earnings and Provides Business Update
Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee On- Going with Top-Line Data Expected in the Second Half of 2022
Histogen Announces CEO Transition
SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...
Histogen and Amerimmune Announce the Presentation of Emricasan Data in COVID-19 at the American College of Allergy, A...
Phase 1 Study in Mild COVID-19 Patients Demonstrated a Favorable Safety and Tolerability Profile and Statistically Significant Clinical Symptom and Biomarker Improvements
Histogen to Report Third Quarter 2021 Financial Results on November 10, 2021
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...
Best Penny Stocks To Buy Under $1 Right Now? 5 To Watch In September
Red hot penny stocks to watch and YES all are under $1 right now. The post Best Penny Stocks To Buy Under $1 Right Now?
Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...
Histogen Shares Additional Emricasan Data From COVID-19 Study
Histogen Inc (NASDAQ: HSTO) and its partner Amerimmune LLC have announced additional findings from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients. As previously reported, emricasan...
Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19...
Immunological Data Highlights How Caspase Inhibition May Prevent COVID-19 Disease Progression
Histogen Reports Second Quarter 2021 Earnings and Provides Business Update
Company to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates
Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...